Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $200.4M beat the $193.2M expected, while GAAP EPS of $0.02 missed the $0.03 mean estimate. Strong performance in Pharma Direct (+76% YoY) and Subscriptions (+39% YoY) helped offset a 26% decline in Prescription Transactions. Despite the top-line beat, elevated tax rates (44.8% vs. 23.4% expected) and cost pressures from new offerings impacted the bottom line.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: GoodRx(GDRX) the Revenue is 200.41 M (-1.31%), Beat estimate;the EBIT is 44.38 M (-15.41%), Beat estimate;the EPS is 0.02 (-50%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.20B1.31%
0.19B4.88%
+0.01B3.57%
EBITExceed expectations
0.04B15.41%
0.04B20.34%
+0.00B4.93%
EPSMiss expectations
0.0250.00%
0.027531.35%
-0.007518.65%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf